Medistim

Regulatory Filings • Oct 10, 2014

Medistim hosts a symposium during the EACTS conference in Milan

Medistim hosts a symposium during the EACTS conference in Milan

(Oslo, 10th of October 2014) Medistim ASA (OSE:

MEDI), a Norwegian company that develops and

commercializes medical equipment for use in cardiac,

vascular and transplant surgery, announces that

clinical data generated by the use of their

ultrasonic systems for control and quality assurance

of coronary bypass surgery will be the subject of a

symposium held during the annual European Association

for Cardiac-Thoracic Surgery (EACTS) conference.

On October 13, Medistim holds a symposium at this

year's EACTS conference which is taking place in

Milan, Italy.

The title of the symposium is "Optimizing

intraoperative decision making during CABG: Luck or

science?" The theme focuses on how the surgeon, by

the use of high resolution epicardial ultrasound

imaging in combination with TTFM (Transit Time Flow

Measurement), has a better tool to assess graft

patency during by-pass surgery.

TTFM has been the leading technology available for

this type of quality assurance, until Medistim

launched their latest systems, offering both TTFM and

intraoperative ultrasound imaging in one system.

Still, with these technologies available, the

majority of the world's surgeons do not use any kind

of objective and technology based quality assurance.

Instead they trust their own subjective assessment.

For example, many choose to palpate the grafts, i.e.

to use their fingers to feel for a pulse and

atheromatous plaque.

The moderator of the symposium is Professor David

Taggart from Oxford University, John Radcliffe, UK.

Professor David Taggart is a world leading cardiac

surgeon, with considerable activity in research and

innovation. Professor Taggart is currently leading

the work to assess the new combination procedure,

TTFM and epicardial ultrasound imaging, as a

potentially new quality assurance method at their

hospital.

Professor Gabriele Di Giammarco at the University

hospital in Chieti, Italy, will give a presentation

during the symposium and share his experiences of

using Medistim's combined solution. Professor Di

Giammarco is one of the most experienced users of

this solution and he published in December 2013 the

article "Intraoperative graft verification in

coronary surgery: Increased diagnostic Accuracy

Adding high-resolution epicardial ultrasonography two

transit-time flow measurement" in the European

Journal of cardio- Thoracic Surgery.

Professor Hirokuni Arai from the University hospital

in Tokyo, Japan, will also give a presentation based

on his experience with the combination. In June this

year, Professor Arai got accepted for publication

of an article in the prestigious journal Circulation.

The topic was a particularly interesting case study

where TTFM and epicardial ultrasound imaging gave

insight into a coronary dissection that might

otherwise not have been detected.

Medistim's system includes both ultrasound imaging

and TTFM measurements in the same system, and is the

only product on the market that combines these two

technologies.

For more information, contact:

President & CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@medistim.com

About Medistim

Medistim was established in 1984, and has a track

record of profitable growth over the past >10 years.

The company is a pioneer within its segment, and

continues to invest in new product development.

Medistim has wholly owned subsidiaries with sales

organizations in the US, Germany, Denmark, UK and

Norway, in addition to the around 50 distributors in

Europe, Asia, Middle East, Africa and South

America. For more information, visit the Medistim

home page: ww.Medistim.com